Department of Pharmacy Practice, College of Pharmacy, Center for Pharmacogenetics, University of Florida, P.O. Box 100486, Gainesville, FL 32610-0486, USA.
Heart Fail Rev. 2010 May;15(3):187-96. doi: 10.1007/s10741-008-9094-x. Epub 2008 Apr 24.
Beta-blockers (metoprolol, bisoprolol, and carvedilol) are a cornerstone of heart failure (HF) treatment. However, it is well recognized that responses to a beta-blocker are variable among patients with HF. Numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to a beta-blocker, including left ventricular ejection fraction improvement, survival, and hospitalization due to HF exacerbation. This review summarizes the pharmacogenetic data for beta-blockers in patients with HF and discusses the potential implications of beta-blocker pharmacogenetics for HF patients.
β 受体阻滞剂（美托洛尔、比索洛尔和卡维地洛）是心力衰竭（HF）治疗的基石。然而，人们已经充分认识到，HF 患者对β 受体阻滞剂的反应存在个体差异。目前大量研究表明，遗传多态性可能导致β 受体阻滞剂反应的变异性，包括左心室射血分数的改善、生存以及因 HF 恶化而住院。本综述总结了 HF 患者使用β 受体阻滞剂的药物遗传学数据，并讨论了β 受体阻滞剂药物遗传学对 HF 患者的潜在影响。
